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Objectives The purpose of this study was to evaluate the association between regional myocardial fibrosis and ventricular
arrhythmias in patients with cardiomyopathy.
Background Patients with heart failure are at risk of sudden cardiac death (SCD). Current guidelines recommend implantable
cardioverter-defibrillator (ICD) devices for a subgroup based on impaired left ventricular function. A significant
proportion of devices never discharge, hence a more accurate method for targeting those at risk is desirable.
Methods We prospectively enrolled 103 patients meeting criteria for ICD implantation for primary prevention of SCD. Car-
diac magnetic resonance imaging was performed before device implantation. Regional fibrosis was identified
with late gadolinium enhancement (LGE).
Results Median follow-up was 573 days (interquartile range: 379 to 863 days). The LGE identified regional fibrosis in 31
of 61 (51%) patients with nonischemic cardiomyopathy (NICM) and in all 42 patients with ischemic cardiomyop-
athy (ICM). There was a 29% (9 of 31) discharge rate in the NICM group with LGE compared with a 14% (6 of
42) discharge rate in the ICM group (p  NS). There were no ICD discharges in the NICM group without LGE,
which was significantly lower than the rate observed in both the ICM patients (p  0.04) and the NICM patients
with LGE (p  0.01). Left ventricular ejection fraction was similar in patients with and without device therapy
(24  12% vs. 26  8%, p  NS) and those with or without LGE (25  9% vs. 26  9%, p  NS).
Conclusions Patients with advanced cardiomyopathy and myocardial fibrosis demonstrated by LGE on cardiac magnetic reso-
nance imaging have a high likelihood of appropriate ICD therapy. Correspondingly, absence of LGE may indicate
a lower risk for malignant ventricular arrhythmias. (J Am Coll Cardiol 2011;57:821–8) © 2011 by the
American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.06.062Sudden cardiac death (SCD) is a major cause of mortality in
patients with advanced heart failure (1), and implantation of
an automatic implantable cardioverter-defibrillator (ICD)
has been found to significantly reduce arrhythmic death in
this population (2,3). Consequently, current clinical guide-
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accepted June 21, 2010.lines recommend ICD insertion for primary prevention of
SCD in a subgroup of patients with heart failure based on
reduced left ventricular ejection fraction (LVEF) (4). Spe-
cifically, ICD therapy is indicated for those with nonisch-
emic cardiomyopathy (NICM) with LVEF35% and New
York Heart Association (NYHA) functional class II or III,
See page 829
and also for those with ischemic cardiomyopathy (ICM)
with LVEF 35% or 30% depending on NYHA functional
class. These guidelines have been predicted to result in as
many as 500,000 Medicare beneficiaries becoming eligible
for ICD implantation in the U.S. alone (5). In this context,
the estimated cost is as high as U.S. $100,000 per quality-
adjusted life year (6). However, the majority of patients with
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prevention never receive device
therapy, with the average rate of
appropriate ICD shocks esti-
mated at 5.1% per year (3).
Moreover, there appear to be a
group of patients with low
LVEF who remain at low risk of
SCD, although predictive mea-
sures are not well validated (7,8).
Therefore, strategies to improve
cost effectiveness of ICD therapy
may reduce the population ex-
posed to unnecessary device im-
plantation while perhaps also
driving earlier implantation in
high-risk patients, which would
be highly desirable.
Recent studies have shown
that presence of myocardial fi-
brosis identified by cardiac mag-
netic resonance imaging (CMRI)
is associated with a poor prognosis in patients with heart
failure (9,10), using a composite end point of cardiovascular
morbidity and overall mortality. While these studies add
important information regarding the significance of myo-
cardial fibrosis, they do not answer the clinical question of
whether myocardial fibrosis predicts likelihood of ICD
therapy. Although the mechanism for pathogenesis of
ventricular arrhythmias in patients with cardiomyopathy is
not well elucidated, there is evidence to suggest it is linked
to presence of myocardial fibrosis, both in ischemic and
nonischemic groups (11–13). Areas of late gadolinium
enhancement (LGE) visualized on CMRI are presumed to
represent macroscopic regions of myocardial fibrosis (14),
and are present in approximately 30% of patients with
NICM (15). We have, therefore, hypothesized that absence
of LGE on CMRI predicts a lower risk of requiring ICD
therapy in patients with devices implanted for primary
prevention of SCD.
Methods
Study design and patient selection. The present study was
performed at the Alfred Hospital, Melbourne, Australia,
between July 2003 and October 2009. Subjects with ad-
vanced heart failure planned for implantation of ICD
according to international guidelines (4) for primary pre-
vention of SCD were invited to participate. Subjects were
excluded if they suffered from claustrophobia, uncontrolled
arrhythmias, or had a history of a metallic prosthetic
implant contraindicating CMRI. No patient with previous
ventricular arrhythmia causing hemodynamic compromise
or requiring treatment was considered for this study. Pa-
tients with recent myocardial infarction (3 months) or
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NYHA  New York Heart
Association
SCD  sudden cardiac
deathmyocarditis were also excluded.Only subjects with successful device implantation and a
minimum of 6 months of follow-up and/or an event
(appropriate device therapy, death, or heart transplantation)
were included in the data analysis. The primary end point of
the study was appropriate device therapy, with a pre-
specified composite secondary end point of appropriate
device therapy, all-cause mortality, and heart transplanta-
tion. The study was carried out with approval of the Alfred
Hospital Ethics Review Committee. The authors had full
access to the data and take responsibility for its integrity. All
authors have read and agree to the manuscript as written.
CMRI protocol. MRI SEQUENCES. We performed CMRI
on 103 subjects with impaired left ventricular (LV) function
on a clinical 1.5-T CMRI scanner (Signa 1.5-T, GE
Healthcare, Waukesha, Wisconsin). All sequences were
acquired during a breath-hold of 10 to 15 s. The LV
function was assessed by a steady-state free precession pulse
sequence (TR  3.8 ms, TE  1.6 ms, 30 phases, slice
thickness 8 mm).
Delayed hyperenhancement was obtained 10 min after a
bolus of gadolinium-DTPA (0.2 mmol/kg, BW Magnevist,
Schering, Berlin, Germany) to identify regional fibrosis
using an inversion-recovery gradient echo technique (TR 
7.1 ms; TE 3.1 ms; TI individually determined to null the
myocardial signal, slice thickness 8 mm, matrix 256  192,
number of acquisitions  2).
All cine CMRI sequences were performed in 3 standard
long-axis and short-axis slices, kept identical for each
sequence throughout the CMRI examination (16). From an
end-diastolic 4-chamber long-axis view, 5 equally spaced
slices were planned, so that the 2 outer slices lined up exactly
either with the tip of the apex or the mitral annulus. The 2
outer slices were then deleted, leaving 3 slices corresponding
to typical basal, mid, and apical short-axis views. Delayed
enhancement imaging was performed in both long-axis and
short-axis views.
EVALUATION OF LV FUNCTION AND REGIONAL FIBROSIS.
The LV function was evaluated globally utilizing the bi-
plane area-length method using 2- and 4-chamber long-axis
views.
Regional fibrosis was identified by delayed enhancement
within the myocardium, defined quantitatively by myocar-
dial post-contrast signal intensity greater than 2 SD above
that within a reference region of remote noninfarcted
myocardium within the same slice. Myocardial delayed
enhancement was assessed in all cases by 2 independent
blinded expert readers and was defined as being present only
if it was identified in both long-axis and short-axis views
(Fig. 1). Ambiguous cases were reviewed using a third
expert reader blinded to patient clinical status and ICD
follow-up details.
ICD implantation and follow-up. All devices were im-
planted using standard surgical technique: choice of device
was at the discretion of the implanting physician and the
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February 15, 2011:821–8 Predicting Device Therapy in Heart Failurebrillation threshold was routinely assessed immediately
post-implant unless the patient was in atrial fibrillation and
not receiving anticoagulation therapy. Initial programming
of the defibrillator at time of implant was for shock only at
a detection rate of 180 beats/min.
During follow-up antitachycardia pacing was only pro-
grammed after an episode of ventricular tachycardia, which
may or may not have resulted in device shock. Device
activation was defined as any therapy including antitachy-
cardia pacing or shocks delivered by the device for ventric-
ular tachyarrhythmias.
Each patient had appropriate sensing confirmed, and
each device was interrogated for recorded events and device
therapy before hospital discharge and at each follow-up.
Device therapy was assessed by an experienced cardiologist
(blinded to CMRI findings and clinical status) and classified
as appropriate if it was a result of ventricular tachyarrhyth-
mia according to established criteria (17–20). Patients were
reviewed according to routine clinical schedule, with regular
follow-up visits at 1 and 6 months after implantation, and
every 6 months thereafter. Additional reviews were per-
formed if clinically indicated. Pharmacological management
and ICD parameter settings were at the discretion of the
treating physician.
Statistics. All data are expressed as mean  1 SD unless
Figure 1 Determining Presence of Myocardial Delayed Enhance
Four-chamber long-axis views (top images) and mid-ventricular short-axis views (bo
endocardial delayed enhancement (left), dilated cardiomyopathy with septal mid-wtherwise indicated. Comparison between 2 groups using bontinuous variables utilized unpaired Student t test. For
rdinal data, the Mann-Whitney U test was used. Analysis
f variance was used for comparison between 2 groups
sing continuous variables. Comparison between groups
sing categorical variables utilized the chi-square test or
isher exact test for small group sizes. The log-rank test was
sed to compare Kaplan-Meier survival curves. Results from
ultiple comparisons were adjusted using the Bonferroni
orrection. All analyses were conducted using SPSS soft-
are (version 17, SPSS, Chicago, Illinois) or SigmaStat
oftware (version 3.5, Systat Software, San Jose, California).
vent (or censoring) times for all patients were measured
rom time of ICD implantation. Patients who had appro-
riate device therapy, received a heart transplant, or died
ere censored at the time of first event. For all comparisons,
p value 0.05 was considered significant, and all reported
values are 2-tailed.
esults
linical and demographic data. A total of 103 subjects
ith successful CMRI and ICD implantation were evalu-
ted (derivation of study population in Fig. 2). Median
ollow-up was 573 days (interquartile range [IQR]: 379 to
63 days). Table 1 shows baseline characteristics of patients
t
images) are shown. Examples depict ischemic cardiomyopathy with regional sub-
osis (center), and dilated cardiomyopathy without delayed enhancement (right).men
ttom
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divided into 3 groups: ICM, NICM with LGE (NICM)
and NICM without LGE (NICM). At CMRI patients
were age 54  13 years with a mean LVEF of 26  9%.
There was no significant difference in LVEF or medication
use between groups; however, a nonsignificant trend to
younger age in the NICM cohort was observed. The study
population contained 61 subjects with NICM (31 NICM,
30 NICM) and 42 subjects with ICM.
CMRI findings. LGE was present in 73 of the 103 (71%)
subjects. All images were assessed by 2 blinded expert
readers with agreement in 99 of 103 (96%) cases, with
adjudication in the remaining 4 by a senior expert blinded
reader. As expected, LGE was identified in all 42 subjects
with ICM, and was present in 31 of 61 (51%) patients with
NICM. In patients with ICM, 28 of 42 (67%) patients had
subendocardial LGE and 36 of 42 (86%) had transmural
Figure 2 Derivation of Study Population
CMR  cardiac magnetic resonance; ICD  implantable
cardioverter-defibrillator; LGE  late gadolinium enhancement.
Baseline CharacteristicsTable 1 Baseline Characteristics
All (n  103) ICM (n  4
Age, yrs 54 13 56 11
LVEF, % 26 9 27 8
LVEDVI, ml/BSA 170 51 167 38
NYHA functional class† 2 (2–3) 2 (2–3)
Male, % 77 88
Amiodarone, % 24 21
ACE inhibitor/ARB, % 95 100
Beta-blocker, % 92 95
Spironolactone, % 56 52
*Nonischemic cardiomyopathy (NICM) with () and without () late ga
as median with interquartile range.ACE  angiotensin-converting enzyme; ARB  angiotensin-receptor blocke
left ventricular ejection fraction; LVEDVI  left ventricular end-diastolic volumLGE (22 of 42 [52%] had both). Myocardial LGE was
single vessel in distribution in 22 of 42 (52%) patients and
was multivessel in distribution in 20 of 42 (48%) patients. In
patients with NICM, 19 of 31 (61%) had midwall LGE and
12 of 31 (39%) had patchy LGE in a nonvascular distribu-
tion. There were more males in the ICM group, with
borderline statistical significance (p  0.05). Mean LVEF
nd left ventricular end diastolic volume (indexed to body
urface area) did not vary significantly between groups
Table 1).
CD follow-up data. During the follow-up period, 15
subjects (6 with ICM, 9 with NICM) received appropriate
device therapies with a median time from device implanta-
tion to first therapy of 211 days (IQR: 86 to 370 days). Of
these 15 patients, 12 (80%) received defibrillation (7 for
ventricular fibrillation and 5 for sustained ventricular tachy-
cardia), with the remaining 3 receiving antitachycardia
pacing for sustained ventricular tachycardia. The average
rate of ventricular tachycardia was 199 beats/min (range 150
to 227 beats/min). All therapies occurred in subjects with
LGE on CMRI (LGE), which resulted in a significant
increase in rate of device therapy in the LGE group
ompared with patients without LGE (21% in LGE
atients vs. 0% in LGE patients, p  0.01). Death
ccurred in 2 subjects in the LGE group and 1 in the
GE group, whereas 8 LGE patients received heart
ransplantation at a median time of 328 days (IQR: 210 to
59 days) after ICD implantation. When subjects were
tratified by device therapy, there was no difference in age,
VEF, or medication use (Table 2).
nalysis of ICD discharge rate by etiology and CMRI
ndings. To further evaluate patient risk, we analyzed the
ata in 3 separate groups. In the NICM subgroup, 31 of 61
51%) had LGE identified on CMRI and 30 of 61 (49%)
ad no LGE. These 2 groups were compared to the 42
atients with ICM (all with LGE on CMRI). There was a
9% (9 of 31) discharge rate in the NICM group
ompared with a 14% (6 of 42) discharge rate in the ICM
roup (p  NS). There was a 0% (0 of 30) discharge rate in
he NICM group, which was significantly lower than the
NICM* (n  31) NICM* (n  30) p Value
50 14 55 14 0.09
25 10 25 9 0.45
176 69 169 46 0.75






m enhancement on cardiac magnetic resonance imaging. †Expressed2)
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February 15, 2011:821–8 Predicting Device Therapy in Heart Failurerate observed in both ICM (p  0.04) and NICM
patients (p  0.01). Kaplan-Meier analysis again showed a
ignificant difference between groups for both device ther-
py and the composite secondary end point (p  0.01)
Figs. 3 and 4, respectively). Analysis between groups found
a lower rate of device therapy and the composite secondary
end point in the NICM group compared with both the
NICM group (p  0.01) and the ICM group (p  0.05).
fter Bonferroni correction, the observed differences be-
ween NICM patients and NICM patients with respect
o ICD discharge rate and the composite secondary end
oint remained significant. There was a nonsignificant trend
o a lower rate of device therapy and composite end point in
he ICM group compared with the NICM group (p 
.08 and p  0.09, respectively).
Stratification of Patients by Device TherapyTable 2 Stratification of Patients by Device
All (n  103) No Dev
Age, yrs 54 13
LVEF, % 26 9
LVEDVI, ml/BSA 170 51
NYHA functional class* 2 (2–3)
Ischemic cardiomyopathy, % 41
Male, % 77
Amiodarone, % 24
ACE inhibitor/ARB, % 95
Beta-blocker, % 92
Spironolactone, % 56
*Expressed as median with interquartile range.
Abbreviations as in Table 1.
Figure 3 Freedom From Device Therapy
Kaplan-Meier analysis of patients with ischemic cardiomyopathy (ICM) (green
line) and patients with nonischemic cardiomyopathy with (NICM) (red line)
and without (NICM) (blue line) late gadolinium enhancement (LGE) on cardiac
magnetic resonance imaging shows a significant difference in device therapy,
with all events occurring in patients with LGE (p  0.01).Of 15 administered ICD therapies (7 for ventricular
brillation and 8 for ventricular tachycardia), 4 of 15 (27%)
ad midwall LGE, 5 of 15 (33%) had patchy LGE in a
onvascular distribution, 3 of 15 (20%) had subendocardial
GE in a vascular distribution, and 3 of 15 (20%) had
ransmural LGE in a vascular distribution. There was no
ssociation between type of LGE morphology and ICD
herapy (p  NS, chi square), nor between any type of scar
orphology and type of arrhythmia (ventricular tachycardia
ersus ventricular fibrillation).
iscussion
he present study of patients with advanced heart failure
ndergoing ICD insertion for primary prevention of SCD
apy
erapy (n  88) Device Therapy (n  15) p Value
 13 49 13 0.13
 8 24 12 0.49
 43 196 81 0.19







Figure 4 Event-Free Survival
Kaplan-Meier analysis using the composite end point of appropriate device
therapy, all-cause mortality, and cardiac transplantation for patients with isch-
emic cardiomyopathy (ICM) (green line), nonischemic cardiomyopathy (NICM)
with (NICM) (red line) and without (NICM) (blue line) late gadolinium
enhancement (LGE) on cardiac magnetic resonance imaging shows improved
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Predicting Device Therapy in Heart Failure February 15, 2011:821–8demonstrates a strong association between presence of
regional fibrosis demonstrated by CMRI and appropriate
ICD therapy. Our data not only support a mechanistic link
between regional fibrosis and malignant ventricular arrhyth-
mias, they also suggest that absence of regional fibrosis
predicts a low risk of ICD therapy. Assessment of patients
with NICM who had LGE on CMRI revealed an ICD
discharge rate at least as high as patients with ICM, with
both groups experiencing a significantly higher risk than
those without LGE on CMRI (with no events occurring in
this subgroup). These findings were independent of LVEF,
left ventricular end diastolic dimensions, or medication use.
Additionally, the difference remained significant when
death and cardiac transplantation were included in the
composite secondary end point, implying our results were
not due to increased mortality/transplantation among pa-
tients without LGE on CMRI.
The pathophysiology of ventricular arrhythmias has been
extensively studied and is thought to have a number of
contributing mechanisms (21). With ICM, the predomi-
nant mechanism is thought to be scar-based re-entry. The
arrhythmogenic substrate in NICM is less well defined;
however, prior studies have demonstrated increased myo-
cardial collagen content as well as regional scarring in
NICM (14,21). In addition, electrophysiological evidence
suggests there is a greater degree of myocardial fibrosis in
patients with sustained monomorphic ventricular tachycar-
dia than in patients without sustained arrhythmias, and that
the site of origin of ventricular tachycardia corresponds to
regions of basal electrogram abnormalities (22). Recently,
it has been demonstrated that myocardial scarring (iden-
tified by CMRI) is associated with ventricular arrhyth-
mias in a cohort of patients with NICM referred for
catheter ablation (23).
Prior studies have correlated myocardial fibrosis detected
by CMRI with ventricular arrhythmias and/or adverse
prognosis (9,10,13). These studies have used combined
primary end points (9,10), inducible arrhythmias (13), or
Holter monitoring data (24). While these studies add
important information regarding the significance of myo-
cardial fibrosis, they do not answer the clinical question of
whether myocardial fibrosis predicts likelihood of ICD
therapy. Our study demonstrated a strong and direct corre-
lation between presence of myocardial fibrosis and appro-
priate device therapy, which to our knowledge has not been
previously shown.
Current clinical guidelines recommend ICD implanta-
tion in a large number of patients with advanced heart
failure using systolic dysfunction as the main criterion. Risk
stratification based on LVEF alone is an inexact method, as
evidenced by the finding that the majority of patients with
ICD implantation never receive appropriate therapy (25).
There has been incomplete translation of these recent
guidelines into clinical practice (26). The reason is probably
multifactorial but is due at least in part to the economic
implications of such widespread device implantation. Cost-benefit analysis, while complex, suggests that in most cases,
the cost comes under the commonly used cut-off point of
U.S. $100,000 per quality-adjusted life year (6,27–29).
However, even with more conservative estimates this would
correspond to an expenditure of several billions of dollars
per year in the U.S. alone (6), a figure that may be
unsustainable.
With these considerations in mind, a technique to accu-
rately identify a subgroup at particularly high risk and
optimize device implantation in this most vulnerable pop-
ulation would be highly advantageous. That would need to
be considered in conjunction with other clinical factors, as
discussed previously (30). In our study, there were no events
in the LGE group, suggesting this subgroup may have a
low risk of SCD. However other recent studies (9,10) have
demonstrated a small number of ICD events even in
patients without LGE; therefore, we would not at this stage
suggest applying this method to stratify ICD implantation
in patients in whom ICD therapy is currently both available
and indicated. Larger multicenter studies are required to
demonstrate the predictive value of delayed enhancement
on risk stratification in cardiomyopathy. That would
require ongoing review, including serial CMRI assess-
ment to detect subsequent development of regional fi-
brosis. Recent evidence also supports a role for a clinical
risk prediction model for assessment of likely benefit
from ICD (31). Although our results are promising,
rather than advocating a single test, we would favor a
combination of clinical factors, including scar imaging, to
provide the best assessment of risk for SCD in this
vulnerable population.
Our study contained a population with multiple etiol-
ogies of cardiomyopathy, including a number with coro-
nary artery disease. Although this could potentially lead
to a bias in favor of the LGE group (due to inclusion of
all those with ICM in this subgroup), it is pertinent to
note that the rate of device therapy did not differ
significantly between patients with ICM and patients
with NICM and LV scar. We also found a very high rate
of LGE in our nonischemic subgroup, perhaps because of
a population with more advanced disease, as a number of
our study participants were being considered for cardiac
transplantation. Previous studies have reported rates of
LGE in NICM in the order of 30% (9,15,32), compared
with 51% in our study. Possibly, the mechanism of
ventricular arrhythmias in advanced heart failure is sim-
ilar in ischemic and nonischemic groups, and the pres-
ence of regional fibrosis is an important substrate in all
etiologies, explaining both the high incidence of LGE
and device therapy in this study. That is also supported by
a recent study of patients with hypertrophic cardiomyop-
athy, demonstrating an association between LGE on
CMRI and ventricular arrhythmias (33). Structural re-
modeling is common to all types of cardiomyopathy with
associated fibrosis, providing an arrhythmogenic focus in
susceptible patients. This theory deserves further explo-
827JACC Vol. 57, No. 7, 2011 Iles et al.
February 15, 2011:821–8 Predicting Device Therapy in Heart Failureration as it may prove useful in identifying patients with
less severe systolic dysfunction (measured by LVEF),
who are also at increased risk of SCD. Presently, methods
to risk stratify this subgroup are limited and subsequently
we remain unable to accurately identify which patients
would benefit from ICD implantation.
LGE also only assesses fibrosis distributed in a patchy/
regional pattern and does not give any information on
diffuse myocardial fibrosis, which is also likely to have a
significant effect on clinical outcome. Quantification of
diffuse fibrosis has thus far been difficult; however, recent
work from our group (34) proposes a CMRI method to
address this problem, and we hope future studies will be able
to assess the prognostic impact of both regional and diffuse
myocardial fibrosis in this patient population.
Study limitations. Assessment of myocardial fibrosis by
LGE as performed in our study has a number of limitations.
We used standard clinical sequences with long-axis and
short-axis views and did not quantify fibrosis volumetrically.
Our sequences did not include coverage of the entire
myocardium, and hence, we could have missed small areas
of fibrosis. However, given the absence of ICD therapy in
the LGE group, such small areas of LGE potentially
missed by our CMRI protocol would be of uncertain clinical
relevance. Furthermore, recent studies (10,24) suggest it is
the presence, not volume, of myocardial fibrosis which is the
important prognostic factor. Therefore, we propose our
method allows for a more practical clinical application of
assessing myocardial fibrosis. Our study was also performed
in a heterogeneous group that included patients with ICM.
Although the utility of myocardial fibrosis as detected with
CMRI as a discriminator for appropriate ICD implantation
is perhaps best suited to patients with NICM, our results
suggest patients with NICM who are found to have LGE
on CMRI may have a risk similar to that of patients with
ischemic pathology. This finding would need to be con-
firmed in a larger study before translation into clinical
practice, as our sample size is small and the rate of device
therapy is relatively low.
Conclusions
In this single-center study, we demonstrated a strong associa-
tion between myocardial LGE and appropriate ICD therapy,
supporting the assertion that ventricular scar is an important
arrhythmic substrate in cardiomyopathy. In addition, patients
without LGE had no appropriate device therapies, suggesting
it may be possible to identify a low-risk patient subgroup that
could be managed conservatively.
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